Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of Nintedanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 4/20 | 0.51 |
| ▸ | FGFR1 known ✓ | P11362 | 4/20 | 0.51 |
| ▸ | KDR known ✓ | P35968 | 4/20 | 0.51 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.51 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.51 |
| ▸ | FGFR2 known ✓ | P21802 | 2/20 | 0.51 |
| ▸ | FGFR4 known ✓ | P22455 | 2/20 | 0.51 |
| ▸ | FGFR3 known ✓ | P22607 | 2/20 | 0.51 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.51 |
| ▸ | MELK | Q14680 | 9/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.50 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.50 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nintedanib SCHEMBL2376201 | 1.00 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL4262453 | 1.00 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL4262457 | 1.00 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL4543205 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL4543201 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL4551728 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL4551730 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL1535871 | 0.99 | AAK1 (0.59) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL431006 | 0.99 | AAK1 (0.59) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL29352914 | 0.99 | AAK1 (0.59) | AAK1PDGFRBFGFR1KDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366689-A1 | Saccharin salts and crystalline salt forms of an 2-indolinone derivative | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-09-21 | — | — | EP | claimed |
| EP-2364969-A1 | Salts and crystalline salt forms of an 2-indolinone derivative | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-09-14 | — | — | EP | claimed |
| EP-2364968-A1 | Salts and crystalline salt forms of an 2-indolinone derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-14 | — | — | EP | claimed |
| US-20090318471-A1 | New Salts and Crystalline Salt Forms of an Indolinone Derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-24 | — | — | US | claimed |
| EP-2029533-A2 | SALTS AND CRYSTALLINE SALT FORMS OF AN 2-INDOLINONE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2009-03-04 | — | — | EP | claimed |
| EP-1870400-A1 | Salts and crystalline salt forms of an 2-indolinone derivative | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-12-26 | — | — | EP | claimed |
| WO-2007141283-A2 | SALTS AND CRYSTALLINE SALT FORMS OF AN 2-INDOLINONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318471-A1 | New Salts and Crystalline Salt Forms of an Indolinone Derivative | REN, SLC6A4, IPO4 | PDGFRB 4309/4885FGFR1 1704/4885KDR 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.